Trastuzumab biosimilar - CuraTeQ Biologics
Alternative Names: BP-02; BP02-TrastuzumabLatest Information Update: 27 Dec 2022
At a glance
- Originator Aurobindo Pharma
- Developer CURATEQ BIOLOGICS PRIVATE LIMITED
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HER2 positive breast cancer
Most Recent Events
- 29 Nov 2022 No development reported - Phase-III for HER2-positive-breast-cancer (Inoperable/Unresectable, Metastatic disease) in Bangladesh (IV) (NDR Batch 25)
- 29 Nov 2022 No development reported - Phase-III for HER2-positive-breast-cancer (Inoperable/Unresectable, Metastatic disease) in India (IV) (NDR Batch 25)
- 17 May 2021 CuraTeQ plans a phase I trial of BP 02 (In volunteers) in New Zealand (IV) (ACTRN12621000573853)